

Disclosure: This table is for informational purposes only. Primary references and full prescribing information should be consulted. Clinicians have the professional responsibility to ensure that drugs are prescribed and used appropriately, based on their own clinical judgment and accepted standards of care.

Name	Regimen	Reference
Single agents		
Capecitabine	1,250 mg/m ² PO bid, days 1–14, followed by 7 days rest <i>Repeat every 3 weeks</i>	Hoff et al. <i>J Clin Oncol.</i> 2001;19:2282-2292.
Irinotecan	125 mg/m ² over 90 minutes, days 1, 8, 15, 22 <i>Repeat every 6 weeks</i>	Saltz et al. <i>N Engl J Med.</i> 2000;343:905-914.
Irinotecan	300 or 350 mg/m ² IV over 90 minutes, day 1 <i>Repeat every 3 weeks</i>	Cunningham et al. <i>Lancet.</i> 1998;352:1413-1418.
Cetuximab	400 mg/m ² IV over 2 hours week 1 followed by 250 mg/m ² IV over 1 hour weekly	Saltz et al. <i>J Clin Oncol.</i> 2004;22:1201-1208.
Combination regimens		
5-FU/LV Roswell Park regimen	LV 500 mg/m ² IV over 2 hours, days 1, 8, 15, 22, 29, 36 5-FU 600 mg/m ² IV bolus 1 hour after start of LV, days 1, 8, 15, 22, 29, 36 <i>Repeat every 8 weeks</i>	Petrelli et al. <i>J Clin Oncol.</i> 1989;7:1419-1426.
5-FU/LV Mayo regimen	LV 20 mg/m ² IV bolus, days 1–5 5-FU 370 mg/m ² IV bolus 1 hour after start of LV, days 1–5 <i>Repeat cycle at 4 and 8 weeks and every 5 weeks thereafter</i>	Poon et al. <i>J Clin Oncol.</i> 1989;7:1407-1418.
5-FU/LV de Gramont regimen (LV5FU2)	LV 200 mg/m ² IV over 2 hours, days 1 and 2 5-FU 400 mg/m ² IV bolus, then 600 mg/m ² IV over 22 hours, days 1 and 2 <i>Repeat every 2 weeks</i>	de Gramont et al. <i>J Clin Oncol.</i> 1997;15:808-815. de Gramont et al. <i>J Clin Oncol.</i> 2000;18:2938-2947.
IFL Saltz regimen	Irinotecan 125 mg/m ² IV over 90 minutes, days 1, 8, 15, 22 LV 20 mg/m ² IV bolus, days 1, 8, 15, 22 5-FU 500 mg/m ² IV bolus, days 1, 8, 15, 22 <i>Repeat every 6 weeks</i>	Saltz et al. <i>N Engl J Med.</i> 2000;343:905-914.
Irinotecan + 5-FU/LV Douillard regimen	Irinotecan 180 mg/m ² over 2 hours, day 1 LV 200 mg/m ² IV over 2 hours prior to 5-FU, days 1 and 2 5-FU 400 mg/m ² IV bolus, then 600 mg/m ² continuous infusion over 22 hours, days 1 and 2 <i>Repeat every 2 weeks</i>	Douillard et al. <i>Lancet.</i> 2000;355:1041-1047.
FOLFIRI	Irinotecan 180 mg/m ² over 90 minutes, day 1 LV 200 mg/m ² over 2-hour infusion during irinotecan 5-FU bolus 400 mg/m ² , then 2.4–3 g/m ² continuous infusion over 46 hours, days 1 and 2 <i>Repeat every 2 weeks</i>	André et al. <i>Eur J Cancer.</i> 1999;35:1343-1347. Tournigand et al. <i>J Clin Oncol.</i> 2004;23:229-237.
Capri	Capecitabine 1,000 mg/m ² PO bid, days 1–14 Irinotecan 100 mg/m ² , days 1 and 8 <i>Repeat every 22 days</i>	Grothey et al. <i>Proc Am Soc Clin Oncol.</i> 2003;22:255. Abstract 1022.
FOLFOX4	Oxaliplatin 85 mg/m ² IV over 2 hours, day 1 LV 200 mg/m ² IV over 2 hours, days 1 and 2 5-FU 400 mg/m ² IV bolus, then 600 mg/m ² IV over 22 hours, days 1 and 2 <i>Repeat every 2 weeks</i>	de Gramont et al. <i>J Clin Oncol.</i> 2000;18:2938-2947. Rothenberg et al. <i>J Clin Oncol.</i> 2003;21:2059-2069.
FOLFOX6	Oxaliplatin 100 mg/m ² IV over 2 hours, day 1 LV 200 mg/m ² IV over 2 hours, day 1 5-FU 400 mg/m ² IV bolus, then 2.4–3 g/m ² over 46 hours, continuous infusion <i>Repeat every 2 weeks</i>	Maindrault-Goebel et al. <i>Eur J Cancer.</i> 1999;35:1338-1342. Tournigand et al. <i>J Clin Oncol.</i> 2004;23:229-237.
mFOLFOX6	Oxaliplatin 85 mg/m ² IV over 2 hours, day 1 LV 175 mg/m ² IV over 2 hours, day 1 5-FU 400 mg/m ² IV bolus, then 2.4–3 g/m ² over 46 hours, continuous infusion <i>Repeat every 2 weeks</i>	Cheeseman et al. <i>Br J Cancer.</i> 2002;87:393-399.

Name	Regimen	Reference
FOLFOX7	Oxaliplatin 130 mg/m ² IV over 2 hours, day 1 LV 400 mg/m ² IV over 2 hours 5-FU 2,400 mg/m ² IV over 46 hours, continuous infusion <i>Repeat every 2 weeks for 6 cycles</i>	André et al. <i>Proc Am Soc Clin Oncol.</i> 2003;22:253. Abstract 1016.
FLOX	Oxaliplatin 85 mg/m ² IV over 2 hours, days 1, 15, 29 LV 500 mg/m ² IV over 2 hours, days 1, 8, 15, 22, 29, 36 5-FU 500 mg/m ² IV bolus <u>1 hour after start of LV</u> , days 1, 8, 15, 22, 29, 36 <i>Repeat every 8 weeks for 3 cycles</i>	Smith et al. <i>Proc Am Soc Clin Oncol.</i> 2003;22:294. Abstract 1181.
FUFOX	Oxaliplatin 60 mg/m ² IV over 2 hours, days 1, 8, 15, 22 LV 500 mg/m ² IV over 2 hours, days 1, 8, 15, 22 5-FU 2.6 g/m ² IV over 24 hours, continuous infusion, days 1, 8, 15, 22 <i>Repeat every 36 days</i>	Moehler et al. <i>Z Gastroenterol.</i> 2002;40:957-964.
bFOL	Oxaliplatin 85 mg/m ² IV over 2 hours, every 2 weeks LV 20 mg/m ² IV over 10–20 minutes, days 1, 8, 15 5-FU 500 mg/m ² IV bolus, days 1, 8, 15 <i>Repeat every 28 days</i>	Hochester et al. <i>J Clin Oncol.</i> 2003;21:2703-2707.
FOLFOX 4 + Bevacizumab	Oxaliplatin 85 mg/m ² IV over 2 hours, day 1 LV 200 mg/m ² IV over 2 hours, days 1 and 2 5-FU 400 mg/m ² IV bolus, then 600 mg/m ² IV over 22 hours, days 1 and 2 Bevacizumab 5 mg/kg IV over 90 minutes,* day 1 <i>Repeat every 2 weeks</i>	de Gramont et al. <i>J Clin Oncol.</i> 2000;18:2938-2947. Rothenberg et al. <i>J Clin Oncol.</i> 2003;21:2059-2069. Avastin [package insert]. South San Francisco, Calif: Genentech, Inc; 2004.
FOLFOX4 + Cetuximab	Oxaliplatin 85 mg/m ² IV over 2 hours, day 1 LV 200 mg/m ² IV over 2 hours, days 1 and 2 5-FU 400 mg/m ² IV bolus, then 600 mg/m ² IV over 22 hours, days 1 and 2 <i>Repeat every 2 weeks</i> Cetuximab 400 mg/m ² IV over 2 hours week 1 followed by 250 mg/m ² IV over 60 minutes weekly	Tabernero et al. <i>Proc Am Soc Clin Oncol.</i> 2004;23:248. Abstract 3512.
XELOX	Oxaliplatin 130 mg/m ² IV over 2 hours, day 1 Capecitabine 1000 mg/m ² PO bid, evening day 1–morning day 15 <i>Repeat every 3 weeks</i>	Van Cutsem et al. <i>Proc Am Soc Clin Oncol.</i> 2003;22:255. Abstract 1023.
XELIRI	Irinotecan 250 mg/m ² IV, day 1 Capecitabine 1,000 mg/m ² PO bid, evening day 1–morning day 15 <i>Repeat every 3 weeks</i>	Patt et al. <i>Proc Am Soc Clin Oncol.</i> 2004;23:271. Abstract 3602.
CapOx	Oxaliplatin 70 mg/m ² IV, days 1 and 8 Capecitabine 1,000 mg/m ² PO bid, days 1–14 <i>Repeat every 22 days</i>	Grothey et al. <i>Proc Am Soc Clin Oncol.</i> 2003;22:255. Abstract 1022.
IROX	Irinotecan 200 mg/m ² IV over 90 minutes, day 1 Oxaliplatin 85 mg/m ² IV over 2 hours, day 1 <i>Repeat every 3 weeks</i>	Goldberg et al. <i>J Clin Oncol.</i> 2004;22:23-30.
IFL + Bevacizumab	Irinotecan 125 mg/m ² IV over 90 minutes, days 1, 8, 15, 22 LV 20 mg/m ² IV, days 1, 8, 15, 22 5-FU 500 mg/m ² IV, days 1, 8, 15, 22 <i>Repeat every 6 weeks</i> Bevacizumab 5 mg/kg IV over 90 minutes* following chemotherapy, day 1 <i>Repeat every 2 weeks</i>	Hurwitz et al. <i>N Engl J Med.</i> 2004;350:2335-2342.

CRC = colorectal cancer; 5-FU = 5-fluorouracil; LV = leucovorin.

12/20/04

*If first infusion is well tolerated, subsequent infusions may be administered over 60 minutes and then 30 minutes.